Universität zu Köln

Balke-Want, H. and Borchmann, P. (2021). CAR T-cell therapy for malignant B-cell lymphoma A new treatment paradigm. Internist, 62 (6). S. 589 - 597. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Full text not available from this repository.

Abstract

Following the first demonstration of efficacy of anti-CD19-directed chimeric antigen receptor (CAR) T cells in a patient with relapsed chronic lymphocytic leukemia (CLL) in 2011, pivotal studies for this innovative therapy were initially conducted in multiple relapsed or refractory (r/r) childhood and young adult acute B-cell leukemia and in aggressive adult B-cell lymphoma. The studies demonstrated efficacy even in chemotherapy-refractory disease, resulting in the first approval of autologous and genetically engineered T cells for the treatment of r/r B-cell acute lymphoblastic leukemia (B-ALL) in the US for the product tisagenlecleucel (Kymriah (R), Novartis) back in 2018. Approval for the treatment of r/r aggressive B-cell lymphoma followed shortly thereafter for tisagenlecleucel and axicabtagene ciloleucel (Yescarta, Kite/Gilead). This review focuses on the treatment of aggressive B-cell lymphoma and other CD19 positive B-cell lymphomas by summarizing the study results of clinically tested CAR T cells, discussing possible resistance mechanisms, and providing an outlook on ongoing studies with new target antigens for the treatment of B-cell lymphomas.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Balke-Want, H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-564913
DOI:	10.1007/s00108-021-01056-3
Journal or Publication Title:	Internist
Volume:	62
Number:	6
Page Range:	S. 589 - 597
Date:	2021
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1289
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OPEN-LABEL; RITUXIMAB; CHEMOTHERAPY; TRANSPLANTATION; GEMCITABINE; RESISTANCE; PHASE-3; YOUNG Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/56491